Table 4.
Meta-analysis results of outcomes reported by studies comparing SRL vs. CsA or TAC a.
| SRL vs. CsA | SRL vs. TAC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome | Study Design (N) | Time (mo.) | Relative Risk b (95% CI) | Statistics c | Study Design (N) | Time (mo.) | Relative Risk b (95% CI) | Statistics c | ||
| p | I2% | p | I2% | |||||||
| Total Infections | RCT [46,61] (927) | 12 | 0.98 (0.82, 1.18) | 0.86 | 33 | − | − | − | − | − |
| CMV | RCT [43,44,46,61] (1,155) | 12 | 0.46 (0.25, 0.85) | 0.01 | 53 d | RCT [47,61] (924) | 12 | 0.26 (0.03,2.30) | 0.23 | 79 |
| UTI | RCT [43,44,46,61] (1,155) | 12 | 1.04 (0.79, 1.37) | 0.79 | 35 | − | − | − | − | − |
| Anemia | RCT [43,46,61] (1,010) | 12 | 1.48 (1.16, 1.90) | <0.01 | 0 | RCT [47,61] (924) | 12 | 1.56 (1.26,1.93) | <0.01 | 0 |
| Leukopenia | RCT [43,46,61] (1,010) | 12 | 1.32 (0.70, 2.47) | 0.39 | 57 e | RCT [47,61] (924) | 12 | 0.82 (0.59,1.14) | 0.24 | 0 |
| Dyslipidemia | RCT [43,46,61] (1,010) | 12 | 2.02 (1.03, 3.97) | 0.04 | 65 f | RCT [47,61] (924) | 12 | 1.58 (1.10,2.26) | 0.01 | 0 |
| Diabetes | RCT [43,44,46,61] (1,155) | 12 | 1.82 (1.14, 2.89) | 0.05 | 0 | RCT [47,61] (924) | 12 | 0.78 (0.52,1.17) | 0.23 | 0 |
| Hypertension | RCT [43,46,61] (1,010) | 12 | 0.94 (0.66, 1.33) | 0.71 | 28 | RCT [47,61] (924) | 12 | 1.53 (0.55,4.23) | 0.41 | 93 |
| Lymphoceles | RCT [44,46,61] (1,072) | 12 | 1.65 (1.10, 2.46) | 0.01 | 18 | RCT [47,61] (924) | 12 | 2.92 (1.73,4.93) | <0.01 | 0 |
| Malignancies | RCT [43,61] (871) | 12 | 1.09 (0.09,13.46) | 0.95 | 60 | − | − | − | − | − |
| Withdraw | RCT [43,44,46,61] (1,155) | 12 | 3.68 (2.22, 6.11) | <0.01 | 0 | RCT [47,61] (924) | 12 | 4.31 (2.32,7.99) | <0.01 | 0 |
Abbreviations: UTI, urinary tract infection. a Results reaching statistical significance are in bold font. b Relatives risk values of <1 favor treatment with SRL. c p: p-value for relative risk estimation; I2: test for heterogeneity. d Sensitivity analysis removing Groth 1998 [43]: RR 0.38 (0.21 to 0.67; I2 = 38%). e Sensitivity analysis removing Groth 1998 [43]: RR 1.0 (0.69 to 1.47; I2 = 0%). f Sensitivity analysis removing Ekberg 2007 [61]: RR 3.01 (1.61 to 5.62; I2 = 0%).